

# Global Travelers Vaccines Market - 2025-2033

<https://marketpublishers.com/r/G52016FE19DEEN.html>

Date: May 2025

Pages: 180

Price: US\$ 4,350.00 (Single User License)

ID: G52016FE19DEEN

## Abstracts

### Global Travelers Vaccines Market - Industry Outlook & Trends

The global traveler's vaccines market reached US\$ 4,092.58 million in 2024 and is expected to reach US\$ 9,054.68 million by 2033, growing at a CAGR of 8.7 % during the forecast period of 2025-2033.

The global traveler's vaccines market encompasses the development, manufacturing, distribution, and administration of vaccines tailored to protect travelers from infectious diseases commonly found or endemic in specific regions worldwide. Also known as travel immunizations, these vaccines are recommended or mandated for individuals traveling internationally to ensure their safety and to help prevent the transmission of diseases across national borders.

Key drivers include the prevalence of vaccine-preventable diseases in travel destinations, expanding tourism infrastructure, and public-private partnerships improving vaccine accessibility and affordability. Opportunities are emerging from the adoption of digital health technologies, the expansion of vaccination centers, and tailored vaccination strategies for specific traveler profiles.

The scope of the market extends across various vaccine types (e.g., hepatitis A, typhoid, yellow fever), travel types (domestic and outbound), and distribution channels, with demand particularly strong for vaccines targeting diseases prevalent in popular tourist destinations.

Industry outlook remains positive, fueled by trends such as the increasing frequency of international travel, the emergence of infectious disease threats, government regulations mandating vaccination, and the growing popularity of combination vaccines that offer protection against multiple diseases.

## Global Travelers Vaccines Market - Dynamics: Drivers & Restraints

### Rising International Travel and Tourism

The surge in international travel and tourism is a primary driver fueling the growth of the global travelers' vaccines market. As global mobility increases, more individuals are traveling to regions where they may be exposed to infectious diseases not prevalent in their home countries. This heightened movement-whether for business, leisure, adventure, or visiting friends and relatives-significantly raises the risk of contracting and spreading vaccine-preventable diseases, thereby boosting demand for travel vaccines.

The direct correlation between rising international travel and increased demand for travel vaccines is evident in the market's robust growth projections. It increases the exposure of travelers to infectious diseases, prompts regulatory vaccination requirements, and heightens health awareness, all of which contribute to sustained and growing demand for travel vaccines worldwide.

Additionally, key players in the industry initiatives that would drive this market growth. For instance, in March 2024, Umrah and Hajj tour operators, along with UAE residents, are seeking further clarification after the Ministry of Health and Prevention (MoHAP) announced that influenza vaccination is now mandatory for all pilgrims traveling to Saudi Arabia. Travelers must present valid influenza vaccination cards as part of the health requirements for entry.

Also, in February 2024, UK retail pharmacies introduced a comprehensive new service to simplify international travel preparation. This service offers travelers personalized counseling based on their travel itinerary, ensuring they receive all required and recommended vaccines for their destination. Available vaccines include yellow fever, Japanese encephalitis, typhoid, and cholera, among others. All these factors demand the global traveler's vaccine market.

### Stringent Regulatory Approvals

Stringent regulatory approvals represent a major restraint in the global traveler's vaccines market due to the complex, lengthy, and resource-intensive processes required to bring a new vaccine to market. These regulatory frameworks are designed to ensure that all vaccines meet the highest standards of safety, efficacy, and quality, but they also introduce several challenges for vaccine developers and manufacturers.

Vaccine development and approval involve multiple stages, including preclinical research, three phases of clinical trials, and extensive review of manufacturing processes and facilities. In the United States, for example, developers must submit an Investigational New Drug (IND) application before clinical trials, followed by phased human trials to assess safety, immunogenicity, and efficacy.

After successful trials, a Biological License Application (BLA) is submitted to the FDA, which undergoes a rigorous review that can take from six months (priority review) to a year (standard review). Similarly, in Europe, developers must submit comprehensive data to the European Medicines Agency (EMA) for scientific evaluation, which typically takes up to 210 days under standard timelines. Thus, the above factors could be limiting the global traveler's vaccine market's potential growth.

### Global Travelers Vaccines Market - Segment Analysis

The global traveler's vaccines market is segmented based on product type, travel type, end-user, and region.

#### Product Type:

The hepatitis A segment was valued at US\$ 1,138.46 million in 2024 and is estimated to reach US\$ 2,436.14 million by 2032, growing at a CAGR of 7.8% during the forecast period from 2025-2033

The Hepatitis A segment is a key component of the global traveler's vaccines market, driven by the need to protect international travelers from the Hepatitis A virus (HAV) infection. Hepatitis A is a highly contagious liver infection transmitted primarily through contaminated food and water, a risk that is especially high in regions with poor sanitation and limited access to clean water.

The demand for Hepatitis A vaccines is driven by both the high prevalence of the disease in popular travel destinations and the effectiveness of the vaccine itself. A single-dose schedule provides substantial short-term protection, while a two-dose series offers long-lasting immunity-often for decades.

Hepatitis A vaccination is strongly recommended for travelers visiting endemic areas, including parts of Africa, Asia, Central and South America, and Eastern Europe. The vaccine is often included in pre-travel health consultations and is one of the most

commonly administered travel vaccines.

For instance, in January 2024, India's launch of its first indigenously developed Hepatitis A vaccine marks a significant milestone in both the national and global travelers' vaccines market. By producing a Hepatitis A vaccine locally, India can offer this crucial immunization at a lower cost compared to imported alternatives. This makes the vaccine more accessible not only to Indian travelers but also to neighboring countries and regions where cost has been a major barrier to vaccination. These factors have solidified the segment's position in the global traveler's vaccines market.

### Global Travelers Vaccines Market – Geographical Analysis

The North America travelers' vaccines market was valued at US\$ 1,754.81 million in 2024 and is estimated to reach US\$ 3,817.62 million by 2033, growing at a CAGR of 8.1% during the forecast period from 2025-2033

North America, particularly the United States and Canada, sees millions of international travelers each year for business, tourism, education, and family visits. This high volume of cross-border movement increases the demand for travel-related vaccinations to protect against region-specific infectious diseases.

The region benefits from advanced healthcare systems, widespread availability of travel clinics, and retail pharmacy vaccination services. This infrastructure ensures easy access to vaccines and pre-travel health consultations, making it convenient for travelers to get immunized. Travelers in North America generally have high awareness of travel health risks and the importance of immunization. Public health campaigns, CDC travel advisories, and educational resources contribute to informed decision-making and higher vaccine uptake rates.

In the U.S. and Canada, health authorities, such as the CDC and Health Canada, regularly update and enforce guidelines for travel vaccinations. Certain destinations require proof of vaccination (e.g., yellow fever), and these regulatory requirements drive compliance among travelers. The market offers a wide range of vaccines, including combination vaccines (e.g., Hepatitis A & B), single-dose options, and vaccines for emerging diseases. Innovation in vaccine technology and delivery methods (such as needle-free injectors) enhances convenience and adoption.

For instance, in March 2025, Bavarian Nordic introduced VIMKUNYA (Chikungunya Vaccine, Recombinant) to the U.S. market, the first virus-like particle (VLP), single-dose

vaccine designed to protect against chikungunya for individuals aged 12 and older. With this launch, VIMKUNYA becomes a significant addition to the global travel health landscape, offering essential protection for travelers heading to regions where the chikungunya virus is endemic. Thus, the above factors are consolidating the region's position as a dominant force in the global travelers' vaccines market.

The Asia-Pacific travelers' vaccines market was valued at US\$ 1,067.91 million in 2024 and is estimated to reach US\$ 2,677.58 million by 2033, growing at a CAGR of 9.5% during the forecast period from 2025-2033

The Asia-Pacific traveler's vaccines market is experiencing strong growth, propelled by increasing international (outbound) and domestic travel, rising awareness of travel-related infectious diseases, and evolving public health policies.

The market covers a broad range of vaccines, including those for cholera, DPT (diphtheria, pertussis, tetanus), encephalitis, hepatitis A and B, meningococcal disease, influenza, rabies, typhoid, yellow fever, and others. These vaccines are administered through various modalities such as chemotherapy, hormone therapy, targeted therapy, immunotherapy, radiation, surgery, and other supportive measures, although vaccination is the primary preventive approach.

Japan plays a significant role in the Asia-Pacific travelers' vaccine market. The country's robust healthcare system, strong regulatory environment, and high levels of public health awareness contribute to a large and growing market for both domestic and outbound traveler vaccinations. Japan's focus on disease prevention, especially for international travelers and during major events, further accelerates market growth.

### Global Travelers Vaccines Market – Competitive Landscape

The major global players in the traveler's vaccines market include GSK plc, Merck & Co., Inc., Bavarian Nordic Inc., Pfizer Inc., Sanofi, Dynavax Technologies, Valneva SE, and Takeda Pharmaceutical Company Limited, among others.

### Global Travelers Vaccines Market – Key Developments

In April 2025, Valneva SE, a specialty vaccine company, announced that the European Commission granted marketing authorization for its single-dose chikungunya vaccine, IXCHIQ, extending its approved use to individuals aged 12 years and older across the European Union, Norway, Liechtenstein, and

Iceland. As the world's first licensed chikungunya vaccine, IXCHIQ addresses a significant unmet medical need and is also approved for adults in the United States, Canada, and the United Kingdom, with similar adolescent label extension applications under review in those countries.

In May 2024, the Ministry of Health and Prevention (MoHAP) urged all pilgrims traveling to Saudi Arabia for Hajj to receive the seasonal influenza vaccine and complete all required immunizations. Pilgrims are advised to ensure they receive the necessary vaccine doses at least 15 days before departure, allowing sufficient time for the vaccines to become effective and provide adequate immunity. Additionally, MoHAP emphasizes that all vaccinations should be documented on the international vaccination card by accredited health centers.

## Contents

### **1. MARKET INTRODUCTION AND SCOPE**

- 1.1. Objectives of the Report
- 1.2. Report Coverage & Definitions
- 1.3. Report Scope

### **2. EXECUTIVE INSIGHTS AND KEY TAKEAWAYS**

- 2.1. Market Highlights and Strategic Takeaways
- 2.2. Key Trends and Future Projections
- 2.3. Snippet by Product Type
- 2.4. Snippet by Travel Type
- 2.5. Snippet by End-User
- 2.6. Snippet by Region

### **3. DYNAMICS**

- 3.1. Impacting Factors
  - 3.1.1. Drivers
    - 3.1.1.1. Rising International Travel and Tourism
    - 3.1.1.2. Adoption of Digital Health Integration
    - 3.1.1.3. XX
  - 3.1.2. Restraints
    - 3.1.2.1. Stringent Regulatory Approvals
    - 3.1.2.2. Lack of Awareness Among Travelers
    - 3.1.2.3. XX
  - 3.1.3. Opportunity
    - 3.1.3.1. Expansion of Travel to Emerging Economies
    - 3.1.3.2. XX
  - 3.1.4. Impact Analysis

### **4. STRATEGIC INSIGHTS AND INDUSTRY OUTLOOK**

- 4.1. Market Leaders and Pioneers
  - 4.1.1. Emerging Pioneers and Prominent Players
  - 4.1.2. Established leaders with the largest-selling Brand
  - 4.1.3. Market leaders with established Product



- 4.2. CXO Perspectives
- 4.3. Latest Developments and Breakthroughs
- 4.4. Regulatory and Reimbursement Landscape
  - 4.4.1. North America
  - 4.4.2. Europe
  - 4.4.3. Asia Pacific
  - 4.4.4. South America
  - 4.4.5. Middle East & Africa
- 4.5. Porter's Five Forces Analysis
- 4.6. Supply Chain Analysis
- 4.7. Patent Analysis
- 4.8. SWOT Analysis
- 4.9. Unmet Needs and Gaps
- 4.10. Recommended Strategies for Market Entry and Expansion
- 4.11. Scenario Analysis: Best-Case, Base-Case, and Worst-Case Forecasts
- 4.12. Pricing Analysis and Price Dynamics
- 4.13. Key Opinion Leaders

## **5. TRAVELERS' VACCINES MARKET, BY PRODUCT TYPE**

- 5.1. Introduction
  - 5.1.1. Analysis and Y-o-Y Growth Analysis (%), By Product Type
  - 5.1.2. Market Attractiveness Index By Product Type
- 5.2. Cholera\*
  - 5.2.1. Introduction
  - 5.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
- 5.3. Diphtheria Pertussis Tetanus (DPT)
- 5.4. Encephalitis
- 5.5. Hepatitis A
- 5.6. Hepatitis B
- 5.7. Meningococcal
- 5.8. Influenza
- 5.9. Rabies
- 5.10. Typhoid
- 5.11. Yellow Fever
- 5.12. Others

## **6. TRAVELERS' VACCINES MARKET, BY TRAVEL TYPE**



## 6.1. Introduction

### 6.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Travel Type

### 6.1.2. Market Attractiveness Index By Travel Type

## 6.2. Domestic\*

### 6.2.1. Introduction

### 6.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)

## 6.3. Outbound

# 7. TRAVELERS' VACCINES MARKET, BY END-USER

## 7.1. Introduction

### 7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User

### 7.1.2. Market Attractiveness Index, By End-User

## 7.2. Hospitals\*

### 7.2.1. Introduction

### 7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)

## 7.3. Travel Clinics

## 7.4. Others

# 8. TRAVELERS' VACCINES MARKET, BY REGIONAL MARKET ANALYSIS AND GROWTH OPPORTUNITIES

## 8.1. Introduction

### 8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region

### 8.1.2. Market Attractiveness Index, By Region

## 8.2. North America

### 8.2.1. Introduction

### 8.2.2. Key Region-Specific Dynamics

### 8.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type

### 8.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Travel Type

### 8.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User

### 8.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country

#### 8.2.6.1. U.S.

#### 8.2.6.2. Canada

#### 8.2.6.3. Mexico

## 8.3. Europe

### 8.3.1. Introduction

### 8.3.2. Key Region-Specific Dynamics

### 8.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type

8.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Travel Type

8.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User

8.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country

8.3.6.1. Germany

8.3.6.2. U.K.

8.3.6.3. France

8.3.6.4. Spain

8.3.6.5. Italy

8.3.6.6. Rest of Europe

8.4. South America

8.4.1. Introduction

8.4.2. Key Region-Specific Dynamics

8.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type

8.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Travel Type

8.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User

8.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country

8.4.6.1. Brazil

8.4.6.2. Argentina

8.4.6.3. Rest of South America

8.5. Asia-Pacific

8.5.1. Introduction

8.5.2. Key Region-Specific Dynamics

8.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type

8.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Travel Type

8.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User

8.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country

8.5.6.1. China

8.5.6.2. India

8.5.6.3. Japan

8.5.6.4. South Korea

8.5.6.5. Rest of Asia-Pacific

8.6. Middle East and Africa

8.6.1. Introduction

8.6.2. Key Region-Specific Dynamics

8.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type

8.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Travel Type

8.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User

## **9. COMPETITIVE LANDSCAPE AND MARKET POSITIONING**

- 9.1. Competitive Overview and Key Market Players
- 9.2. Market Share Analysis and Positioning Matrix
- 9.3. Strategic Partnerships, Mergers & Acquisitions
- 9.4. Key Developments in Product Portfolios and Innovations
- 9.5. Company Benchmarking

## **10. COMPANY PROFILES**

- 10.1. GSK plc.\*
  - 10.1.1. Company Overview
  - 10.1.2. Product Portfolio
    - 10.1.2.1. Product Description
    - 10.1.2.2. Product Key Performance Indicators (KPIs)
    - 10.1.2.3. Historic and Forecasted Product Sales
    - 10.1.2.4. Product Sales Volume
  - 10.1.3. Financial Overview
    - 10.1.3.1. Company Revenue
    - 10.1.3.2. Geographical Revenue Shares
    - 10.1.3.3. Revenue Forecasts
  - 10.1.4. Key Developments
    - 10.1.4.1. Mergers & Acquisitions
    - 10.1.4.2. Key Product Development Activities
    - 10.1.4.3. Regulatory Approvals, etc.
  - 10.1.5. SWOT Analysis
- 10.2. Merck & Co, Inc.
- 10.3. Bavarian Nordic Inc.
- 10.4. Pfizer Inc.
- 10.5. Sanofi
- 10.6. Dynavax Technologies.
- 10.7. Valneva SE.
- 10.8. Takeda Pharmaceutical Company Limited.

LIST NOT EXHAUSTIVE

## **11. ASSUMPTIONS AND RESEARCH METHODOLOGY**

- 11.1. Data Collection Methods
- 11.2. Data Triangulation
- 11.3. Forecasting Techniques

#### 11.4. Data Verification and Validation

### **12. APPENDIX**

#### 12.1. About Us and Services

#### 12.2. Contact Us

## List Of Tables

### LIST OF TABLES

Table 1 Global Travelers Vaccines Market Value, By Product Type, 2025, 2029 & 2033 (US\$ Million)

Table 2 Global Travelers Vaccines Market Value, By Travel Type, 2025, 2029 & 2033 (US\$ Million)

Table 3 Global Travelers Vaccines Market Value, By End-User, 2025, 2029 & 2033 (US\$ Million)

Table 4 Global Travelers Vaccines Market Value, By Region, 2025, 2029 & 2033 (US\$ Million)

Table 5 Global Travelers Vaccines Market Value, By Product Type, 2025, 2029 & 2033 (US\$ Million)

Table 6 Global Travelers Vaccines Market Value, By Product Type, 2022-2033 (US\$ Million)

Table 7 Global Travelers Vaccines Market Value, By Travel Type, 2025, 2029 & 2033 (US\$ Million)

Table 8 Global Travelers Vaccines Market Value, By Travel Type, 2022-2033 (US\$ Million)

Table 9 Global Travelers Vaccines Market Value, By End-User, 2025, 2029 & 2033 (US\$ Million)

Table 10 Global Travelers Vaccines Market Value, By End-User, 2022-2033 (US\$ Million)

Table 11 Global Travelers Vaccines Market Value, By Region, 2025, 2029 & 2033 (US\$ Million)

Table 12 Global Travelers Vaccines Market Value, By Region, 2022-2033 (US\$ Million)

Table 13 North America Travelers Vaccines Market Value, By Product Type, 2022-2033 (US\$ Million)

Table 14 North America Travelers Vaccines Market Value, By Travel Type, 2022-2033 (US\$ Million)

Table 15 North America Travelers Vaccines Market Value, By End-User, 2022-2033 (US\$ Million)

Table 16 North America Travelers Vaccines Market Value, By Country, 2022-2033 (US\$ Million)

Table 17 South America Travelers Vaccines Market Value, By Product Type, 2022-2033 (US\$ Million)

Table 18 South America Travelers Vaccines Market Value, By Travel Type, 2022-2033 (US\$ Million)

Table 19 South America Travelers Vaccines Market Value, By End-User, 2022-2033 (US\$ Million)

Table 20 South America Travelers Vaccines Market Value, By Country, 2022-2033 (US\$ Million)

Table 21 Europe Travelers Vaccines Market Value, By Product Type, 2022-2033 (US\$ Million)

Table 22 Europe Travelers Vaccines Market Value, By Travel Type, 2022-2033 (US\$ Million)

Table 23 Europe Travelers Vaccines Market Value, By End-User, 2022-2033 (US\$ Million)

Table 24 Europe Travelers Vaccines Market Value, By Country, 2022-2033 (US\$ Million)

Table 25 Asia-Pacific Travelers Vaccines Market Value, By Product Type, 2022-2033 (US\$ Million)

Table 26 Asia-Pacific Travelers Vaccines Market Value, By Travel Type, 2022-2033 (US\$ Million)

Table 27 Asia-Pacific Travelers Vaccines Market Value, By End-User, 2022-2033 (US\$ Million)

Table 28 Asia-Pacific Travelers Vaccines Market Value, By Country, 2022-2033 (US\$ Million)

Table 29 Middle East and Africa Travelers Vaccines Market Value, By Product Type, 2022-2033 (US\$ Million)

Table 30 Middle East and Africa Travelers Vaccines Market Value, By Travel Type, 2022-2033 (US\$ Million)

Table 31 Middle East and Africa Travelers Vaccines Market Value, By End-User, 2022-2033 (US\$ Million)

Table 32 Middle East and Africa Travelers Vaccines Market Value, By Country, 2022-2033 (US\$ Million)

Table 33 GSK plc.: Overview

Table 34 GSK plc.: Product Portfolio

Table 35 GSK plc: Key Developments

Table 36 Merck & Co, Inc.: Overview

Table 37 Merck & Co, Inc.: Product Portfolio

Table 38 Merck & Co, Inc.: Key Developments

Table 39 Bavarian Nordic Inc.: Overview

Table 40 Bavarian Nordic Inc.: Product Portfolio

Table 41 Bavarian Nordic Inc.: Key Developments

Table 42 Pfizer Inc.: Overview

Table 43 Pfizer Inc.: Product Portfolio

Table 44 Pfizer Inc.: Key Developments

Table 45 Sanofi: Overview

Table 46 Sanofi: Product Portfolio

Table 47 Sanofi: Key Developments

Table 48 Dynavax Technologies: Overview

Table 49 Dynavax Technologies: Product Portfolio

Table 50 Dynavax Technologies: Key Developments

Table 51 Valneva SE.: Overview

Table 52 Valneva SE.: Product Portfolio

Table 53 Valneva SE.: Key Developments

Table 54 Takeda Pharmaceutical Company Limited: Overview

Table 55 Takeda Pharmaceutical Company Limited: Product Portfolio

Table 56 Takeda Pharmaceutical Company Limited: Key Developments



## List Of Figures

### LIST OF FIGURES

- Figure 1 Global Travelers Vaccines Market Value, 2022-2033 (US\$ Million)
- Figure 2 Global Travelers Vaccines Market Share, By Product Type, 2024 & 2033 (%)
- Figure 3 Global Travelers Vaccines Market Share, By Travel Type, 2024 & 2033 (%)
- Figure 4 Global Travelers Vaccines Market Share, By End-User, 2024 & 2033 (%)
- Figure 5 Global Travelers Vaccines Market Share, By Region, 2024 & 2033 (%)
- Figure 6 Global Travelers Vaccines Market Y-o-Y Growth, By Product Type, 2023-2033 (%)
- Figure 7 Cholera Travelers Vaccines Market Value, 2022-2033 (US\$ Million)
- Figure 8 Diphtheria Pertussis Tetanus (DPT) Travelers Vaccines Market Value, 2022-2033 (US\$ Million)
- Figure 9 Encephalitis Travelers Vaccines Market Value, 2022-2033 (US\$ Million)
- Figure 10 Hepatitis A Travelers Vaccines Market Value, 2022-2033 (US\$ Million)
- Figure 11 Hepatitis B Travelers Vaccines Market Value, 2022-2033 (US\$ Million)
- Figure 12 Meningococcal Travelers Vaccines Market Value, 2022-2033 (US\$ Million)
- Figure 13 Influenza Travelers Vaccines Market Value, 2022-2033 (US\$ Million)
- Figure 14 Rabies Travelers Vaccines Market Value, 2022-2033 (US\$ Million)
- Figure 15 Typhoid Travelers Vaccines Market Value, 2022-2033 (US\$ Million)
- Figure 16 Yellow Fever Travelers Vaccines Market Value, 2022-2033 (US\$ Million)
- Figure 17 Others Travelers Vaccines Market Value, 2022-2033 (US\$ Million)
- Figure 18 Global Travelers Vaccines Market Y-o-Y Growth, By Travel Type, 2023-2033 (%)
- Figure 19 Domestic Travel Type in Global Travelers Vaccines Market Value, 2022-2033 (US\$ Million)
- Figure 20 Outbound Travel Type in Global Travelers Vaccines Market Value, 2022-2033 (US\$ Million)
- Figure 21 Global Travelers Vaccines Market Y-o-Y Growth, By End-User, 2023-2033 (%)
- Figure 22 Hospitals End-User in Global Travelers Vaccines Market Value, 2022-2033 (US\$ Million)
- Figure 23 Travel Clinics End-User in Global Travelers Vaccines Market Value, 2022-2033 (US\$ Million)
- Figure 24 Other End-Users in Global Travelers Vaccines Market Value, 2022-2033 (US\$ Million)
- Figure 25 Global Travelers Vaccines Market Y-o-Y Growth, By Region, 2023-2033 (%)
- Figure 26 North America Travelers Vaccines Market Value, 2022-2033 (US\$ Million)

Figure 27 North America Travelers Vaccines Market Share, By Product Type, 2024 & 2033 (%)

Figure 28 North America Travelers Vaccines Market Share, By Travel Type, 2024 & 2033 (%)

Figure 29 North America Travelers Vaccines Market Share, By End-User, 2024 & 2033 (%)

Figure 30 North America Travelers Vaccines Market Share, By Country, 2024 & 2033 (%)

Figure 31 South America Travelers Vaccines Market Value, 2022-2033 (US\$ Million)

Figure 32 South America Travelers Vaccines Market Share, By Product Type, 2024 & 2033 (%)

Figure 33 South America Travelers Vaccines Market Share, By Travel Type, 2024 & 2033 (%)

Figure 34 South America Travelers Vaccines Market Share, By End-User, 2024 & 2033 (%)

Figure 35 South America Travelers Vaccines Market Share, By Country, 2024 & 2033 (%)

Figure 36 Europe Travelers Vaccines Market Value, 2022-2033 (US\$ Million)

Figure 37 Europe Travelers Vaccines Market Share, By Product Type, 2024 & 2033 (%)

Figure 38 Europe Travelers Vaccines Market Share, By Travel Type, 2024 & 2033 (%)

Figure 39 Europe Travelers Vaccines Market Share, By End-User, 2024 & 2033 (%)

Figure 40 Europe Travelers Vaccines Market Share, By Country, 2024 & 2033 (%)

Figure 41 Asia-Pacific Travelers Vaccines Market Value, 2022-2033 (US\$ Million)

Figure 42 Asia-Pacific Travelers Vaccines Market Share, By Product Type, 2024 & 2033 (%)

Figure 43 Asia-Pacific Travelers Vaccines Market Share, By Travel Type, 2024 & 2033 (%)

Figure 44 Asia-Pacific Travelers Vaccines Market Share, By End-User, 2024 & 2033 (%)

Figure 45 Asia-Pacific Travelers Vaccines Market Share, By Country, 2024 & 2033 (%)

Figure 46 Middle East and Africa Travelers Vaccines Market Value, 2022-2033 (US\$ Million)

Figure 47 Middle East and Africa Travelers Vaccines Market Share, By Product Type, 2024 & 2033 (%)

Figure 48 Middle East and Africa Travelers Vaccines Market Share, By Travel Type, 2024 & 2033 (%)

Figure 49 Middle East and Africa Travelers Vaccines Market Share, By End-User, 2024 & 2033 (%)

Figure 50 GSK plc.: Financials

Figure 51 Merck & Co, Inc.: Financials

Figure 52 Bavarian Nordic Inc.: Financials

Figure 53 Pfizer Inc.: Financials

Figure 54 Sanofi: Financials

Figure 55 Dynavax Technologies: Financials

Figure 56 Valneva SE.: Financials

Figure 57 Takeda Pharmaceutical Company Limited: Financials

## I would like to order

Product name: Global Travelers Vaccines Market - 2025-2033

Product link: <https://marketpublishers.com/r/G52016FE19DEEN.html>

Price: US\$ 4,350.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/G52016FE19DEEN.html>